◼ Archived
Business
🔮 fades ✓
Novartis’s Latest Trial Setback Sinks Stock
Novartis’s stock tumbles as a second Phase III failure shatters hopes for its Avidity acquisition.
Pharma M&A
2 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Pharma M&A
This hub groups 2 separate news trends connected to Pharma M&A, spanning August 31, 2026 through September 8, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 22 article observations and 16 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
Eli Lilly's $2.88 billion acquisition of Merida Biosciences is poised to reshape the autoimmune disease treatment landscape.